<DOC>
	<DOCNO>NCT00189826</DOCNO>
	<brief_summary>To evaluate compare efficacy safety dual regimen oral modify release tacrolimus FK506E ( MR4 ) / steroid versus dual regimen oral tacrolimus FK506 / steroids patient undergo primary liver transplantation . It shall demonstrate FK506E ( MR4 ) non-inferior FK506 regard primary endpoint .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy FK506E ( MR4 ) Patients Undergoing Primary Liver Transplantation .</brief_title>
	<detailed_description>A multicentre , 1:1 randomise , double blind , double dummy , two arm parallel group phase III study compare dual modify release FK506E ( MR4 ) / steroid regimen standard tacrolimus FK506 / steroid regimen .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients receive primary , split liver whole liver graft cadaveric donor compatible ABO blood type . Patients receive multiorgan transplant previously receive organ transplant ( include liver retransplantation ) . Patients severe diarrhoea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus . Patients serum creatinine &gt; 200 Âµmol/l..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Liver transplantation</keyword>
</DOC>